Core Viewpoint - The company, Watson Pharmaceuticals, has received approval from the Chongqing Municipal Drug Administration for the re-registration of eight pharmaceutical products, indicating a positive regulatory development for the company [1] Group 1: Approved Products - The approved products include: - Injection of Moxifloxacin Mesylate (0.2g and 0.4g) - Injection of Cytidine Diphosphate Choline - Injection of Acyclovir - Xylometazoline Capsules - Injection of Bumetanide - Injection of Calcium Leucovorin (25mg and 100mg) [1]

Core Viewpoint - The company has successfully passed the consistency evaluation for its injectable Acyclovir, enhancing its product pipeline and market competitiveness while gaining experience for future evaluations [1] Group 1: Product Development - The injectable Acyclovir is indicated for the treatment of herpes simplex virus infections, shingles, and chickenpox in immunocompromised patients [1] - The approval of the consistency evaluation will enrich the company's product line [1] Group 2: Market Position - The successful evaluation is expected to improve the company's market competitiveness [1] - The experience gained from this evaluation will facilitate the consistency evaluation of other products in the future [1]